To further develop its innovative probes for image-guided surgery of cancer and conduct first-in-human trials Intrace Medical SA is currently raising the next investment round. Should you be interested in participating in the investment round or would like to receive detailed information please contact us…
  • contact@intrace-medical.com

Surgical resection of tumor remains the major method of choice when treating cancer. Like decades ago surgeons use visual inspection and palpation to identify the tumor. In most cases it is impossible to distinguish tumor margin or recognize small tumors. Incomplete removal of the tumor often leads to cancer recurrence. Real-time fluorescence image-guided surgery offers a solution to this problem.

Development of specific targeting and activatable near-infrared fluorescent probes for clinical image-guided surgery heavily relies on the availability
of high quality NIR florescent dyes for imaging application. Currently the only NIR fluorescent dye allowed to be used in clinic is Indocyanine Green (ICG). However, it possesses numerous drawbacks such as low water solubility, high non-specific binding, high uptake in the liver, low quantum yield (brightness). In addition, ICG in its clinical form cannot be conjugated with biomolecules to form specific probes.


Intrace Medical in collaboration with EPFL has developed a new family of NIR fluorescent dyes operating in > 800 nm region for imaging application and acquired full rights for worldwide commercial development.

The new dye of Intrace Medical has got excellent physico-chemical and biological properties perfectly suitable for the development of probes for imaging application be it clinical image-guided surgery, veterinary surgery or probes for preclinical laboratory research.

  • excellent water solubility
  • high brightness in aqueous environment
  • high stability
  • low non-specific binding to proteins
  • rapid renal clearance
  • can easily be functionalized to make conjugate

Conjugates on the basis of the new dye have successfully been tested first on small laboratory animals and then in the course of veterinary image-guided cancer surgery on dog patients with clear identification of tumor margin.